Bedaquiline resistance probability to guide treatment decision making for rifampicin-resistant tuberculosis: insights from a qualitative study

BACKGROUND: Bedaquiline (BDQ) is a core drug for rifampicin-resistant tuberculosis (RR-TB) treatment. Accurate prediction of a BDQ-resistant phenotype from genomic data is not yet possible. A Bayesian method to predict BDQ resistance probability from next-generation sequencing data has been proposed...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Pham Hien Trang, Anlay, Degefaye Zelalem, Dippenaar, Anzaan, Conceição, Emilyn Costa, Loos, Jasna, Van Rie, Annelies
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682818/
https://www.ncbi.nlm.nih.gov/pubmed/36418994
http://dx.doi.org/10.1186/s12879-022-07865-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682818/
https://www.ncbi.nlm.nih.gov/pubmed/36418994
http://dx.doi.org/10.1186/s12879-022-07865-7

Ejemplares similares